文献速递胸部肿瘤放疗

HL301在不可切除非小细胞肺癌接受根治性同步放化疗患者放射性肺炎中的安全性与疗效:一项多中心、随机、双盲、安慰剂对照、2a期临床试验

Safety and Efficacy of HL301 In Radiation Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer Receiving Curative Concurrent Chemoradiotherapy: A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 2a Clinical Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-03-31

本研究为多中心、随机、双盲、安慰剂对照2a期试验,计划入组87例但因入组率低实际入组63例不可切除非小细胞肺癌患者,随机接受安慰剂(A组)、HL301 1200 mg(B组)或1800 mg(C组),同步每周紫杉醇+卡铂及60-66 Gy调强放疗,HL301口服每日12周。主要终点为放化疗后24周≥2级放射性肺炎发生率,三组分别为37.5%、55.6%、52.4%(P=.535),安全性可行但未观察到疗效信号。

要点

  • HL301在不可切除非小细胞肺癌根治性同步放化疗患者中安全可行,未发生严重药物相关不良事件。
  • 放化疗后24周≥2级放射性肺炎发生率三组分别为37.5%、55.6%、52.4%(P=.535),无显著差异。
  • 该剂量水平下未观察到HL301降低放射性肺炎的疗效信号。

核心结论

  • 这是首个测试HL301在非小细胞肺癌患者中安全性与疗效的探索性临床试验,HL301的安全性和可行性得到确立,但在该剂量水平未观察到降低放射性肺炎的疗效信号。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照2a期临床试验,计划入组87例,因入组率低实际入组63例。
  • 63例不可切除非小细胞肺癌患者随机分为安慰剂组(A组)、HL301 1200 mg组(B组)和HL301 1800 mg组(C组)。
  • 患者接受每周紫杉醇+卡铂同步60-66 Gy常规分割调强放疗,度伐利尤单抗按标准临床实践作为维持治疗,HL301口服每日12周。
  • 主要终点为放化疗后24周≥2级放射性肺炎发生率。

主要发现

  • 患者基线特征均衡,A、B、C组服药依从率分别为86.6%、86.2%、88.8%(P=.874)。
  • 无患者发生严重药物相关不良事件,治疗组间不良事件发生率无显著差异。
  • 放化疗后24周≥2级放射性肺炎发生率A组37.5%(95%CI 18.5%-61.4%)、B组55.6%(95%CI 33.7%-75.4%)、C组52.4%(95%CI 32.4%-71.7%)(P=.535)。

局限性

  • 因入组率低,实际入组63例,未达到计划入组87例。
  • 原文结论指出在该剂量水平未观察到降低放射性肺炎的疗效信号。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We aimed to investigate the safety and efficacy of HL301, a standardized combination product of 7 medicinal plants, in radiation pneumonitis in patients with unresectable non-small cell lung cancer undergoing curative concurrent chemoradiotherapy. METHODS AND MATERIALS: The target accrual was 87 and a total of 63 patients were enrolled due to poor accrual rate. We randomly assigned the 63 patients to receive a placebo (arm A), or 1200 mg HL301 (arm B), or 1800 mg HL301 (arm C). Patients received weekly paclitaxel and carboplatin concurrently with intensity-modulated radiation therapy at 60 to 66 Gy in conventional fractionation. Durvalumab was administered as a maintenance treatment according to standard clinical practice. HL301 was administered orally, daily for 12 weeks. The primary endpoint was incidence of grade ≥2 radiation pneumonitis at 24 weeks postchemoradiotherapy. RESULTS: The baseline characteristics of the patients were well balanced. The drug was tolerable with a compliance rate of 86.6%, 86.2%, and 88.8% in arms A, B, and C, respectively (P = .874). None of the patients experienced severe drug-related adverse events. No significant difference in the rate of adverse events were observed between the treatment arms. The incidence of grade ≥2 radiation pneumonitis at 24 weeks postchemoradiotherapy was 37.5% (95% CI, 18.5%-61.4%), 55.6% (95% CI, 33.7%-75.4%), and 52.4% (95% CI, 32.4%-71.7%) in arms A, B, and C, respectively (P = .535). CONCLUSIONS: This is the first exploratory clinical trial to test the safety and efficacy of HL301 in patients with non-small cell lung cancer. Safety and feasibility of HL301 were established but no signals of efficacy in reducing radiation pneumonitis was observed in this dose level.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Kim KH, Kang N, Song SY, et al. Safety and Efficacy of HL301 In Radiation Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer Receiving Curative Concurrent Chemoradiotherapy: A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 2a Clinical Trial. Int J Radiat Oncol Biol Phys. 2024. PMID: 38565405. doi:10.1016/j.ijrobp.2024.03.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。